BioAtla, Inc. (OTCPK: BCAB)
Health Care · Biotechnology · US
$1.79
+19.33% today · -94.3% 1Y
BioAtla, Inc. (OTCPK: BCAB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.98M and employs 41 people.
Over the last twelve months the share price has lost 94.3%, trading between 1.07 and 71.50.
Tweenvest scores BioAtla, Inc. across four factors: quality 10/100, value 53/100. Its strongest factor is value.
BCAB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.98M
- Revenue (TTM)
- $8.50M
- P/E
- —
- EPS
- -22.74
- Dividend yield
- —
- Beta (5Y)
- 0.70
- 52-week high
- $71.50
- 52-week low
- $1.07
- Avg volume (3M)
- —
- Shares outstanding
- 1.67M
- Employees
- 41
- Next earnings
- —
About BioAtla, Inc.
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
- ISIN
- US09077B2034
- Founded
- 2007
- Listed since
- Dec 16, 2020
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| GeoVax Labs, Inc.NasdaqCM: GOVX | $3.25M | $0.36 | -22.92% |
| ExpreS2ion Biotech Holding AB (publ)OM: EXPRS2 | $3.18M | Skr1.32 | +5.60% |
| Alaunos Therapeutics, Inc.NasdaqCM: TCRT | $3.05M | $1.20 | -20.53% |
| Quest PharmaTech Inc.TSXV: QPT | $3.03M | CA$0.03 | — |
| Silo Pharma, Inc.NasdaqCM: SILO | $2.92M | $1.84 | -12.38% |
| Telo Genomics Corp.TSXV: TELO | $2.88M | CA$0.04 | -11.11% |
| Genprex, Inc.NasdaqCM: GNPX | $2.83M | $3.45 | -0.29% |
| Vaccinex, Inc.OTCPK: VCNX | $2.68M | $1.00 | -4.76% |
Figures last refreshed Sep 20, 2026.